CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform.

CordenPharma has commissioned new GMP capacities at its site in Frankfurt, Germany to manufacture early clinical phase peptide APIs for pharma and biotech customers. The...

CordenPharma and pHLIP have announced their strategic alliance to collaborate in developing and commercializing the pHLIP-LNP targeted delivery platform for RNA-based and...

CDMO CordenPharma, a specialist in active pharmaceutical ingredients (APIs), excipients, drug products and packaging services, inaugurated an increased commercial peptide...

CordenPharma is expanding strategically into synthetic oligonucleotide manufacturing at its plant at Boulder in the US state of Colorado. The two-phase investment is...

Together with Munich’s Ludwig Maximilian University (LMU) and the Humboldt University of Berlin (HU Berlin), German companies Wacker Chemie and CordenPharma International...

German CDMO CordenPharma, a specialist in Active Pharmaceutical Ingredients (APIs), excipients, drug products and packaging services (APIs), is investing more than €10...

Private equity investor Astorg has signed a binding agreement with International Chemical Investors Group (ICIG) to acquire Plankstadt, Germany-based CDMO CordenPharma...